Global Viral Vectors Market Analysis, Drivers & Challenges During the Forecast Period, 2020-2024 - ResearchAndMarkets.com

The "Viral Vectors Market by Application and Geography - Forecast and Analysis 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Global Viral Vectors Market: About this market

The viral vectors market analysis considers sales from both gene therapy and vaccines applications. Our study also finds the sales of viral vectors in Asia, Europe, North America, and ROW. In 2019, the gene therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as easy purification into high titers to mediate targeted gene delivery and its prolonged gene expression with nominal side effects will play a significant role in the gene therapy segment to maintain its market position. Also, our global viral vectors market report looks at factors such as rising prevalence of chronic diseases, increasing use of viral vectors to develop gene therapies and vaccines, and growing funding on and investments in gene therapies and vaccines. However, challenges associated with production and manufacturing of viral vectors, presence of stringent regulatory policies, and risks associated with viral vectors may hamper the growth of the viral vectors industry over the forecast period.

Global Viral Vectors Market: Overview

Rising prevalence of chronic disease

The development of therapies using viral vectors is in high demand due to the growing incidence of various life-threatening diseases such as diabetes, heart disease, HIV, cancer, and hemophilia A. Researchers are using viral vectors to develop curative therapies for cancer diseases such as bladder cancer, melanoma of the skin, lung and bronchus cancer, and other types of cancers. This is because viral vectors are a promising tool for the development of vaccines and gene therapy. Thus, the rising prevalence of chronic disease will lead to the expansion of the global viral vectors market at a CAGR of over 18% during the forecast period.

Emergence of novel technologies to manufacture viral vectors

The use of viral gene transfer vectors has increased owing to the approval of therapies, the initiation of late-stage clinical trials for the treatment of genetic disorders and multiple forms of cancer, and the need for the prevention of infectious diseases through vaccination. With an increased interest in and the widespread adoption of viral vectors by biopharmaceutical industries, there is a need to engineer safe and efficacious vectors and develop robust, scalable, and cost-effective production platforms for industrialization. Furthermore, adeno-associated virus vectors are among most commonly applied virus vectors for in vivo gene therapy as they can transduce non-dividing and dividing cells resulting in long-term and robust transgene expression. This development is expected to have a positive impact on the overall market growth.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

• Preface
• Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis
• Value chain analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

• Market segmentation by application
• Comparison by application
• Gene therapy - Market size and forecast 2019-2024
• Vaccines - Market size and forecast 2019-2024
• Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2019-2024
• Europe - Market size and forecast 2019-2024
• Asia - Market size and forecast 2019-2024
• ROW - Market size and forecast 2019-2024
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

• Increasing number of R&D activities for development of gene therapies
• and vaccines using viral vectors
• Rising number of M&A and collaborations
• Emergence of novel technologies to manufacture viral vectors

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Asklepios BioPharmaceutical Inc.
• Batavia Biosciences BV
• Cobra Biologics Ltd.
• Creative Biogene
• FinVector Oy
• Lonza Group Ltd.
• Merck KGaA
• Novasep Holding SAS
• Oxford Biomedica Plc
• Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ayhc0k